Adverse events associated with budesonide nasal irrigation reported to the US Food and Drug Administration: 2007 to 2022

Abstract

KEYPOINTS Between 2007 and 2022, the FDA received 119 US‐based reports mentioning budesonide nasal irrigation. Most reports were submitted by patients and alerted FDA to off‐label usage of budesonide. Notable adverse events reported to the FDA included headache, dyspnea, and blurred vision.